Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adynxx, Inc.ALQA · Entity 155807 | Director | June 30, 2017 | July 03, 2017 |
| Beyond Air, Inc.AITB · Entity 8379 | Director | March 14, 2017 | April 19, 2017 |
| MetaStat, Inc.MTST · Entity 170270 | Director | October 11, 2017 | November 21, 2017 |
| NEXGEL, INC.NXGL · Entity 8400 | Director | June 25, 2025 | June 28, 2025 |
| NexImmune, Inc.NEXI · Entity 89921 | Executive VP of Research & Dev | April 05, 2022 | April 07, 2022 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| SOLIGENIX, INC.SNGX · Entity 8067 | Director | October 12, 2026 | October 13, 2026 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | See Remarks | November 26, 2018 | November 27, 2018 |
| Streamex Corp.BSGM · Entity 1816 | Director | July 14, 2020 | July 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adynxx, Inc.
Report date June 30, 2017 · Filed July 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2027-06-30 | Direct | 90,000 |
Reported balance
After 2017-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-30 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests in eleven equal monthly installments with one-eleventh (1/11) vesting on the thirtieth (30th) day of each of the next eleven (11) months (or, if there is no 30th day in a month, on the last day of that month), with the first such vesting date occurring on July 30, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in eleven equal monthly installments with one-eleventh (1/11) vesting on the thirtieth (30th) day of each of the next eleven (11) months (or, if there is no 30th day in a month, on the last day of that month), with the first such vesting date occurring on July 30, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.
Beyond Air, Inc.
Report date March 14, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,927 |
Reported balance
Holding disclosure · report date 2017-03-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,927 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2024-07-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The options vest in 3 equal annual installments beginning on July 11, 2014. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2025-09-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The options vest in 3 equal annual installments beginning on September 3, 2015. |
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2025-09-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The restricted shares will become exercisable in 3 equal annual installments beginning on September 3, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 3 equal annual installments beginning on July 11, 2014.
F2: The restricted shares will become exercisable in 3 equal annual installments beginning on September 3, 2015.
F3: The options vest in 3 equal annual installments beginning on September 3, 2015.
MetaStat, Inc.
Report date October 11, 2017 · Filed November 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2017-10-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-11 · Exercise / conversion · Acquired 50,000 · Balance 50,000 F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock.
F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control.
NEXGEL, INC.
Report date June 25, 2025 · Filed June 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2035-06-25 | Direct | 30,000 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 30,000 · Balance 30,000 F1: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors until; the Issuer's 2026 Annual Meeting of Stockholder. The number of shares underlying the stock option shall vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to the Reporting Person's continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors until; the Issuer's 2026 Annual Meeting of Stockholder. The number of shares underlying the stock option shall vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to the Reporting Person's continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan.
NexImmune, Inc.
Report date April 05, 2022 · Filed April 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2032-04-04 | Direct | 80,100 |
Reported balance
After 2022-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-05 · Grant · Acquired 80,100 · Balance 80,100 F1: 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,500 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 22,500 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
SOLIGENIX, INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $549.60 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-12 · Disposition to issuer · Disposed 54 · Balance 0 F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $400.80 · Expires 2028-09-26 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-12 · Disposition to issuer · Disposed 74 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $232.80 · Expires 2029-09-05 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-12 · Disposition to issuer · Disposed 128 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $472.80 · Expires 2030-09-15 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-12 · Disposition to issuer · Disposed 63 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $247.20 · Expires 2031-09-22 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Disposition to issuer · Disposed 121 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.00 · Expires 2032-11-16 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-12 · Disposition to issuer · Disposed 192 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.
Sorrento Therapeutics, Inc.
Report date November 26, 2018 · Filed November 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2028-11-26 | Direct | 100,000 |
Reported balance
After 2018-11-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-26 · Grant · Acquired 100,000 · Balance 100,000 F1: 1/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the original number of shares subject to the option shall vest on November 26, 2019 and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after November 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Streamex Corp.
Report date July 14, 2020 · Filed July 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units ("RSUs")SEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2020-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-14 · Grant · Acquired 50,000 · Balance 50,000 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock. F2: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of common stock.
F2: This RSU award was granted on July 14, 2020 (the "Date of Grant"). The first 16,666 RSUs of this award shall vest and become issuable on July 14, 2021, and the remaining 33,334 RSUs shall vest in substantially equal quarterly installments and become issuable on the last day of each of the next seven calendar quarters, with the last remaining RSUs vesting and becoming issuable on the third anniversary of the Date of Grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the terms and conditions of the issuer's standard form of Restricted Stock Unit Award Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 192 | $0.00 Strike: $156.00 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 6 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires 2032-11-16 Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 121 | $0.00 Strike: $247.20 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 5 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121 shares Expires 2031-09-22 Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 63 | $0.00 Strike: $472.80 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 4 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63 shares Expires 2030-09-15 Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 128 | $0.00 Strike: $232.80 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 3 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128 shares Expires 2029-09-05 Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74 | $0.00 Strike: $400.80 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74 shares Expires 2028-09-26 Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 14:09 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | Disposition to issuerStock Option (Right to Buy) · Derivative | 54 | $0.00 Strike: $549.60 | $0.00 |
DisclosureSEC source: 0001433982-26-000006 · form4-10132026_021050.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54 shares Expires 2027-06-07 F1 · kind: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:12 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 78,947 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001433982-26-000004 · form4-09182026_080938.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Underlying: Common Stock · 78,947 shares Expires 2036-06-16 F1 · derivative.exercise_date: The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001433982-26-000002 · form4-01062026_050115.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001433982-26-000002 · form4-01062026_050115.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| June 25, 2025 Filed Jun 28, 2025 00:00 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001641172-25-016991 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-25 F1 · derivative.exercise_date: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors until; the Issuer's 2026 Annual Meeting of Stockholder. The number of shares underlying the stock option shall vest as follows: in equal 2,500 share amounts over the continuous twelve months (on the last calendar day of each month) beginning on July 31, 2025, subject to the Reporting Person's continuous service through each vesting date. In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:27 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 17,647 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-25-017860 · form4-06202025_080655.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,647 Underlying: Common Stock · 17,647 shares Expires 2035-06-20 F1 · derivative.exercise_date: The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001030 · form4-01072025_050132.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001030 · form4-01072025_050132.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 21:22 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 8,646 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001415889-24-029298 · form4-12132024_091246.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,646 Underlying: Common Stock · 8,646 shares Expires 2034-12-12 F1 · derivative.exercise_date: The stock option vests ratably on each of March 12, 2025, June 12, 2025, September 12, 2025 and December 12, 2025. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · derivative · entry 9 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · derivative · entry 8 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,667 | $52.39 | $192,114.13 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 7 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.02 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,634 | $51.43 | $135,466.62 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 6 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,167 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.86 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,699 | $50.52 | $287,913.48 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 5 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,801 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to 50.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $30.86 | $370,320.00 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 4 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,187 | $52.42 | $167,062.54 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 3 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,500 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.10 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,813 | $51.44 | $453,340.72 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,687 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.10 to $52.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $51.00 | $612,000.00 |
DisclosureSEC source: 0001415889-24-028287 · form4-12042024_051205.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024 Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:54 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantWarrant to Purchase Common Stock · Derivative | 1,818 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001493152-24-047434 · ownership.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,818 Underlying: Common Stock · 1,818 shares Expires 2029-11-20 F1 · kind: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's registered direct offering. The Reporting Person agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of the shares of common stock and the shares of common stock underlying the warrant for a period of 180 days following November 20, 2024. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:54 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 3,636 | $2.75 | $9,999.00 |
DisclosureSEC source: 0001493152-24-047434 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,664 F1 · acquired: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's registered direct offering. The Reporting Person agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of the shares of common stock and the shares of common stock underlying the warrant for a period of 180 days following November 20, 2024. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 21:27 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001493152-24-036900 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: CommonStock · 25,000 shares Expires 2034-09-13 F1 · derivative.exercise_date: Represents a stock option granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended (the "Plan"), for services as a member of the Issuer's Board of Directors. The number of shares underlying to stock option shall vest as follows: 6,250 shares of common stock shall vest as of September 30, 2024 and the remaining 18,750 shares of common stock shall vest in equal 2,084 share amounts at the end of each month over the following continuous nine months beginning on October 31, 2024 (with 2,078 shares vesting on June 30, 2025 due to rounding adjustments). In the event of a Change in Control (as defined in the Plan), any unvested shares underlying the stock option shall accelerate in accordance with the terms of the Plan. Read SEC document |
| August 23, 2024 Filed Aug 28, 2024 01:13 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantWarrant to Purchase Common Stock · Derivative | 5,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001493152-24-034094 · ownership.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-08-23 F1 · kind: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's registered direct offering. The Reporting Person agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of the shares of common stock and the shares of common stock underlying the warrant for a period of 180 days following August 23, 2024 Read SEC document |
| August 23, 2024 Filed Aug 28, 2024 01:13 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 10,000 | $2.50 | $25,000.00 |
DisclosureSEC source: 0001493152-24-034094 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,028 F1 · acquired: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's registered direct offering. The Reporting Person agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of the shares of common stock and the shares of common stock underlying the warrant for a period of 180 days following August 23, 2024 Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $26.42 | $0.00 |
DisclosureSEC source: 0001415889-24-014552 · form4-05242024_050501.xml · derivative · entry 3 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 20,000 | $38.24 | $764,800.00 |
DisclosureSEC source: 0001415889-24-014552 · form4-05242024_050501.xml · nonDerivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,500 F1 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $38.20 to $38.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 20,000 | $26.42 | $528,400.00 |
DisclosureSEC source: 0001415889-24-014552 · form4-05242024_050501.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004102 · form4-02162024_040221.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004102 · form4-02162024_040221.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| December 15, 2023 Filed Dec 15, 2023 21:10 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 38,136 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001415889-23-016529 · form4-12152023_041211.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,136 Underlying: Common Stock · 38,136 shares Expires 2033-12-14 F1 · derivative.exercise_date: The stock option vests ratably on each of March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:34 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001493152-23-029653 · ownership.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended, for past services as a member of the Issuer's Board of Directors. The total number of shares vested as of August 17, 2023. Read SEC document |
| May 26, 2023 Filed May 30, 2023 20:05 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 5,000 | $2.34 | $11,688.50 |
DisclosureSEC source: 0001493152-23-019457 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,028 F1 · price: The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $2.3377 per share. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000673 · form4-01092023_090104.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000673 · form4-01092023_090104.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 21:33 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 46,154 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001415889-22-011632 · form4-11212022_091105.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,285 Underlying: Common Stock · 46,154 shares Expires 2032-11-16 F1 · derivative.exercise_date: The stock option vests ratably on each of February 17, 2023, May 17, 2023, August 17, 2023 and November 17, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 19:12 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (Right to Buy) · Derivative | 80,100 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-22-023746 · doc4.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Executive VP of Research & Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,100 Underlying: Common Stock · 80,100 shares Expires 2032-04-04 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:07 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 5,300 | $1.89 | $10,010.11 |
DisclosureSEC source: 0001104659-22-038736 · tm2210631-4_4seq1.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,028 F1 · price: The Reporting Person purchased the 5,300 shares of common stock in the open market. The $1.8887 represents a weighted average price. The Reporting Person purchased 5,200 shares of common stock at a price of $1.89 per share and 100 shares of common stock at a price of $1.88 per share. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000387 · edgar.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000387 · edgar.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| December 27, 2021 Filed Jan 3, 2022 21:46 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantWarrant to Purchase Common Stock · Derivative | 9,091 | $0.01 Strike: $5.50 | $90.91 |
DisclosureSEC source: 0001104659-22-000438 · tm221361-5_4seq1.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,091 Underlying: Common Stock · 9,091 shares Expires 2026-12-26 F1 · kind: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's underwritten public offering which closed on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Jan 3, 2022 21:46 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 9,091 | $5.49 | $49,909.59 |
DisclosureSEC source: 0001104659-22-000438 · tm221361-5_4seq1.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,728 F1 · acquired: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's underwritten public offering which closed on December 27, 2021. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 20:12 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 29,126 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-21-119301 · tm2128426-3_4seq1.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,126 Underlying: Common Stock · 29,126 shares Expires 2031-09-22 F1 · security: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022. F1 · derivative.exercise_date: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022. Read SEC document |
| May 14, 2021 Filed May 18, 2021 21:00 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | SaleCommon Stock | 3,000 | $0.90 | $2,700.60 |
DisclosureSEC source: 0001213900-21-027682 · ownership.xml · nonDerivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,917 F1 · kind: The Reporting Person's sale of 3,000 shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the purchase of 3,000 shares of the Issuer's common stock reported herein. The Reporting Person has voluntarily agreed to disgorge to the Issuer the full amount of the resulting statutory "profit" calculated pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 14, 2021 Filed May 18, 2021 21:00 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 3,000 | $0.89 | $2,664.00 |
DisclosureSEC source: 0001213900-21-027682 · ownership.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,917 Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:39 UTC | NEXGEL, INC. NONE · Entity 8400 | GrantOption to Purchase Common Stock · Derivative | 666,667 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-21-035612 · tm219618-3_4seq1.xml · derivative · entry 2 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,667 Underlying: Common Stock · 666,667 shares Expires 2031-03-08 F1 · derivative.exercise_date: All of these options vested immediately. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:30 UTC | NexImmune, Inc. NEXI · Entity 89921 | PurchaseCommon Stock | 5,882 | $17.00 | $99,994.00 |
DisclosureSEC source: 0001209191-21-012366 · doc4.xml · nonDerivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Executive VP of Research & Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,882 F1 · shares: Reflects shares purchased in the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.